ANNEXON, INC. Research and Development Expense
ANNEXON, INC. (ANNX) reported Research and Development Expense of $46.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- ANNEXON, INC. research and development expense for the quarter ending 2026-06-30 was $46.59M, a 5.50% increase year-over-year.
- ANNEXON, INC. research and development expense for the quarter ending 2026-03-31 was $35.79M, a 25.72% decline year-over-year.
- ANNEXON, INC. research and development expense for the quarter ending 2025-12-31 was $42.66M, a 1.60% decline year-over-year.
- ANNEXON, INC. research and development expense for the quarter ending 2025-09-30 was $49.70M, a 65.09% increase year-over-year.
- ANNEXON, INC. research and development expense for fiscal 2025 was $184.70M, a 54.63% increase from fiscal 2024.
- ANNEXON, INC. research and development expense for fiscal 2024 was $119.45M, a 5.00% increase from fiscal 2023.
- ANNEXON, INC. research and development expense for fiscal 2023 was $113.76M, a 1.12% increase from fiscal 2022.
- ANNEXON, INC. research and development expense for fiscal 2022 was $112.50M, a 12.43% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.59M 10-Q · filed 2026-08-12 | $82.38M 10-Q · filed 2026-08-12 | $125.03M derived: sum of 3 quarters · filed 2026-08-12 | $174.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $35.79M 10-Q · filed 2026-05-07 | $78.44M derived: sum of 2 quarters · filed 2026-05-07 | $128.15M derived: sum of 3 quarters · filed 2026-05-07 | $172.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $42.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $92.36M derived: sum of 2 quarters · filed 2026-03-30 | $136.52M derived: sum of 3 quarters · filed 2026-08-12 | $184.70M 10-K · filed 2026-03-30 |
| 2025-09-30 | $49.70M 10-Q · filed 2025-11-10 | $93.86M derived: sum of 2 quarters · filed 2026-08-12 | $142.04M 10-Q · filed 2025-11-10 | $185.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $44.16M 10-Q · filed 2026-08-12 | $92.34M 10-Q · filed 2026-08-12 | $135.69M derived: sum of 3 quarters · filed 2026-08-12 | $165.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $48.18M 10-Q · filed 2026-05-07 | $91.53M derived: sum of 2 quarters · filed 2026-05-07 | $121.64M derived: sum of 3 quarters · filed 2026-05-07 | $146.66M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $43.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $73.46M derived: sum of 2 quarters · filed 2026-03-30 | $98.48M derived: sum of 3 quarters · filed 2026-03-30 | $119.45M 10-K · filed 2026-03-30 |
| 2024-09-30 | $30.11M 10-Q · filed 2025-11-10 | $55.13M derived: sum of 2 quarters · filed 2025-11-10 | $76.09M 10-Q · filed 2025-11-10 | $99.36M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $25.03M 10-Q · filed 2025-08-14 | $45.99M 10-Q · filed 2025-08-14 | $69.26M derived: sum of 3 quarters · filed 2025-08-14 | $97.15M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $20.96M 10-Q · filed 2025-05-12 | $44.23M derived: sum of 2 quarters · filed 2025-05-12 | $72.12M derived: sum of 3 quarters · filed 2025-05-12 | $102.37M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $23.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $51.16M derived: sum of 2 quarters · filed 2025-03-03 | $81.41M derived: sum of 3 quarters · filed 2025-03-03 | $113.76M 10-K · filed 2025-03-03 |
| 2023-09-30 | $27.89M 10-Q · filed 2024-11-14 | $58.14M derived: sum of 2 quarters · filed 2024-11-14 | $90.49M 10-Q · filed 2024-11-14 | $119.02M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $30.25M 10-Q · filed 2024-08-12 | $62.60M 10-Q · filed 2024-08-12 | $91.13M derived: sum of 3 quarters · filed 2024-08-12 | $118.99M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $32.34M 10-Q · filed 2024-05-13 | $60.88M derived: sum of 2 quarters · filed 2024-05-13 | $88.74M derived: sum of 3 quarters · filed 2024-05-13 | $117.85M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $28.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $56.40M derived: sum of 2 quarters · filed 2024-03-26 | $85.50M derived: sum of 3 quarters · filed 2024-03-26 | $112.50M 10-K · filed 2024-03-26 |
| 2022-09-30 | $27.86M 10-Q · filed 2023-11-13 | $56.97M derived: sum of 2 quarters · filed 2023-11-13 | $83.97M 10-Q · filed 2023-11-13 | $111.18M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $29.11M 10-Q · filed 2023-08-07 | $56.10M 10-Q · filed 2023-08-07 | $83.32M derived: sum of 3 quarters · filed 2023-08-07 | $110.90M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $27.00M 10-Q · filed 2023-05-08 | $54.22M derived: sum of 2 quarters · filed 2023-05-08 | $81.80M derived: sum of 3 quarters · filed 2023-05-08 | $106.37M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $27.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $54.80M derived: sum of 2 quarters · filed 2023-03-06 | $79.37M derived: sum of 3 quarters · filed 2023-03-06 | $100.07M 10-K · filed 2023-03-06 |
| 2021-09-30 | $27.58M 10-Q · filed 2022-11-03 | $52.15M derived: sum of 2 quarters · filed 2022-11-03 | $72.85M 10-Q · filed 2022-11-03 | $90.84M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $24.57M 10-Q · filed 2022-08-08 | $45.27M 10-Q · filed 2022-08-08 | $63.26M derived: sum of 3 quarters · filed 2022-08-08 | $75.03M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $20.70M 10-Q · filed 2022-05-09 | $38.69M derived: sum of 2 quarters · filed 2022-05-09 | $50.46M derived: sum of 3 quarters · filed 2022-05-09 | $59.75M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $17.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $29.77M derived: sum of 2 quarters · filed 2022-03-01 | $39.05M derived: sum of 3 quarters · filed 2022-03-01 | $49.27M 10-K · filed 2022-03-01 |
| 2020-09-30 | $11.78M 10-Q · filed 2021-11-09 | $21.06M derived: sum of 2 quarters · filed 2021-11-09 | $31.28M 10-Q · filed 2021-11-09 | $38.07M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $9.29M 10-Q · filed 2021-08-16 | $19.50M 10-Q · filed 2021-08-16 | $26.30M derived: sum of 3 quarters · filed 2021-08-16 | $33.39M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $10.22M 10-Q · filed 2021-05-17 | $17.01M derived: sum of 2 quarters · filed 2021-05-17 | $24.10M derived: sum of 3 quarters · filed 2021-05-17 | $30.09M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $13.88M derived: sum of 2 quarters · filed 2021-03-25 | $19.87M derived: sum of 3 quarters · filed 2021-03-25 | $24.52M 10-K · filed 2021-03-25 |
| 2019-09-30 | $7.09M 10-Q · filed 2020-11-16 | $13.08M derived: sum of 2 quarters · filed 2020-11-16 | $17.73M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $5.99M 10-Q · filed 2020-09-08 | $10.64M 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |